Aktie FOREST LABORATORIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Forest Laboratories, Inc.

Aktien

US3458381064

Schlusskurs Nyse
Andere Börsenplätze
- USD - Intraday Chart für Forest Laboratories, Inc.
2016 Devisen: Euro fällt zum USD weiter - Hinweise auf US-Zinserhöhung belasten AW

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Forest Laboratories : Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest
Forest Laboratories : Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
Forest Laboratories : Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
Forest Laboratories : Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Forest Laboratories : to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
Forest Laboratories : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®
Forest Laboratories : COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management
Forest Laboratories : Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Forest Laboratories : Announces Intention to Continue Marketing Both NAMENDA® TABLETS and Once-Daily NAMENDA XR® Into the Fall of 2014
Forest Laboratories : Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Forest Laboratories : Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
Forest Laboratories : Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Forest Laboratories : to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference
Forest Laboratories : to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting
Forest Laboratories : Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest
Actavis : Factbox - M&A frenzy transforming global pharma
Actavis : M&A frenzy in healthcare sector
Forest Laboratories : to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting
Forest Laboratories : Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014
Forest Laboratories : Reports Fiscal Year Fourth Quarter 2014
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Forest Laboratories, Inc.
  5. Andere Sprachen